Advertisement
Advertisement
EDIT
Editas Medicine, Inc. Common Stock
2.02
USDSponsored
+0.03
+1.26%
Feb 02, 15:50 UTC -5
Closed
After-Market
2.01
-0.01
-0.25%
EDIT Earnings Reports
Positive Surprise Ratio
EDIT beat 22 of 40 last estimates.
55%
Next Report
Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.71M
/-$0.26
Implied change from Q3 25 (Revenue/ EPS)
-24.34%
/-7.14%
Implied change from Q4 24 (Revenue/ EPS)
-81.35%
/-52.73%
Editas Medicine, Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, EDIT reported earnings of -0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.30 USD, resulting in a 7.35% surprise. Revenue reached 7.54 million, compared to an expected 5.12 million, with a 47.32% difference. The market reacted with a +2.02% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 5.71 million USD, implying an decrease of -7.14% EPS, and decrease of -24.34% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Editas Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Editas Medicine, Inc. Common Stock reported EPS of -$0.28, beating estimates by 7.35%, and revenue of $7.54M, 47.32% above expectations.
How did the market react to Editas Medicine, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 2.02%, changed from $2.47 before the earnings release to $2.52 the day after.
When is Editas Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for Editas Medicine, Inc. Common Stock's next earnings report?
Based on 16
analysts, Editas Medicine, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of $5.71M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement